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Abstract
Background: It has been suggested that mineralocorticoid receptor antagonists have direct cardioprotective properties,
because these drugs reduce mortality in patients with heart failure. In murine models of myocardial infarction,
mineralocorticoid receptor antagonists reduce infarct size. Using gene deletion and pharmacological approaches, it has
been shown that extracellular formation of the endogenous nucleoside adenosine is crucial for this protective effect. We
now aim to translate this finding to humans, by investigating the effects of the selective mineralocorticoid receptor
antagonist eplerenone on the vasodilator effect of the adenosine uptake inhibitor dipyridamole, which is a well-validated
surrogate marker for extracellular adenosine formation.
Methods and Results: In a randomised, double-blinded, placebo-controlled, cross-over study we measured the forearm
blood flow response to the intrabrachial administration of dipyridamole in 14 healthy male subjects before and after
treatment with placebo or eplerenone (50 mg bid for 8 days). The forearm blood flow during administration of
dipyridamole (10, 30 and 100 mg?min21?dl21) was 1.63 (0.60), 2.13 (1.51) and 2.71 (1.32) ml?dl21?min21 during placebo use,
versus 2.00 (1.45), 2.68 (1.87) and 3.22 (1.94) ml?dl21?min21 during eplerenone treatment (median (interquartile range);
P= 0.51). Concomitant administration of the adenosine receptor antagonist caffeine attenuated dipyridamole-induced
vasodilation to a similar extent in both groups. The forearm blood flow response to forearm ischemia, as a stimulus for
increased formation of adenosine, was similar during both conditions.
Conclusion: In a dosage of 50 mg bid, eplerenone does not augment extracellular adenosine formation in healthy human
subjects. Therefore, it is unlikely that an increased extracellular adenosine formation contributes to the cardioprotective
effect of mineralocorticoid receptor antagonists.
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Introduction
Despite state-of-the-art reperfusion strategies, mortality and
morbidity in patients with an acute myocardial infarction remain
significant. This is caused, at least in part, by ’lethal reperfusion
injury’ [1]. Therefore, novel therapeutic options to further limit
ischemia-reperfusion (IR) injury are urgently needed to improve
outcome in these patients.
It has been suggested that the mineralocorticoid receptor (MR)
antagonists spironolactone and eplerenone could potentially serve
this goal, because these drugs reduce mortality in patients with
heart failure [2–4]. Indeed, recent studies in murine models of
myocardial infarction have shown that MR antagonists can
directly limit infarct size [5–8], and have beneficial effects on left
ventricular remodeling [9,10].
The underlying mechanisms of the infarct size-limiting effect are
not yet fully understood, but it has been suggested that the
endogenous purine nucleoside adenosine is crucially involved.
Adenosine is an endogenous purine nucleoside, which is formed by
intra-, and extracellular degradation of adenosine monophosphate
by the enzyme ecto-5’-nucleotidase (CD73). Degradation of
adenosine only occurs in the intracellular compartment. As a
consequence, facilitated diffusion of adenosine over the cellular
membrane by the equilibrative nucleoside transporter (ENT) is
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normally directed inwards. Stimulation of membrane-bound
adenosine receptors (A1, A2A, A2B, and A3) induces various effects,
including vasodilation, inhibition of inflammation, and protection
against IR-injury. Indeed, endogenous adenosine acts as a key
mediator of the infarct size-limiting effect of several drugs,
including statins and metformin [11,12]. A recent series of
experiments, using genetic and pharmacological approaches in
mouse and rat models of myocardial infarction, convincingly
demonstrated that the cardioprotective effects of the MR
antagonists eplerenone and canrenoate were crucially dependent
on extracellular adenosine formation by CD73 and adenosine
receptor stimulation [6].
Based on these previous animal studies, we now hypothesize
that MR antagonists increase the extracellular adenosine concen-
tration by activating CD73, which has previously also been
reported for statins [13], and we aim to test this hypothesis in
humans in vivo. Measurement of circulating endogenous adeno-
sine is extremely difficult [14], because the half life of adenosine in
blood is very short, due to rapid uptake and degradation by
circulating erythrocytes [15]. Therefore, we used the vasodilator
effect of the ENT inhibitor dipyridamole as a read-out for
endogenous adenosine formation by CD73, as previously
described by our group [16,17]. The results of this study will give
novel insight into the pharmacology of MR antagonists, which can
be used to optimize pharmacological cardioprotective strategies,
for example avoid the use of adenosine receptor antagonists, such
as caffeine, in patients treated with MR antagonists.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study population
After approval by the Institutional Review Board of our centre,
we included 14 healthy male volunteers. They had no history of
cardiovascular disease or asthma, did not smoke and did not use
any medication. In all participants we performed a physical
examination, electrocardiography, and laboratory investigation to
exclude cardiovascular and pulmonary disease, hypertension (SBP
.140 mmHg or DBP .90 mmHg), hypotension (SBP ,
100 mmHg or DBP ,60 mmHg), diabetes mellitus (fasting
venous glucose .6.9 mmol/l or random glucose of .
11.0 mmol/l), renal dysfunction (MDRD ,60 mL/min), liver
enzyme abnormalities (alanine aminotransferase (ALAT) twice
upper limit), and hyperkalemia (plasma potassium $4.8 mmol/l).
All volunteers provided written informed consent before
enrollment. The study was conducted in accordance with Good
Clinical Practices and the Declaration of Helsinki and was
prospectively registered at ClinicalTrials.gov by number
NCT01837108.
Study design
We performed a single center, double-blinded, randomised,
placebo-controlled cross-over study. Tablets of 50 mg of epler-
enone were over-encapsulated and fully mimicking placebos were
created by the Department of Clinical Pharmacy of the Radboud
University Medical Centre. Randomization was performed by the
Department of Clinical Pharmacy and the randomization code
was kept at this department until after analyses and locking of the
database. Study medication was taken bid during 8 days. We
advised the participants to have a diet low in potassium. On the 7th
and 8th day of treatment, we measured forearm blood flow (FBF)
with the use of venous occlusion plethysmography. After a wash-
out period of at least 4 weeks, the participants crossed-over to the
alternative treatment arm. Blood pressure was measured at
baseline, on day 3–5, on day 7 and 8.
Venous occlusion plethysmography
All experiments were performed in a temperature-controlled
room (2460.5uC), in the morning after an overnight fast and at
least 24 hours of caffeine and alcohol abstinence. On the days of
the experiments, 75 minutes after supervised intake of the study
drug, a 27-gauge needle (B. Braun Medical B.V.) was inserted into
the brachial artery of the non-dominant arm for intra-arterial drug
administration. Fifteen minutes later, baseline FBF was measured
during the infusion of normal saline. During the experiment, the
total volume infused into the brachial artery was kept constant at
100 ml?min21?dl21 of forearm volume. We measured FBF in both
arms with venous occlusion plethysmography, using mercury-in-
silastic-strain gauges. The hand circulation was occluded during
the measurements, as described previously [18]. Drugs were
administered for 5 minutes per dose. On day 7, we performed 3
experiments, which were all separated by a wash-out period of 30
minutes to prevent any cross-over effects.
1) We measured FBF during the administration of incremental
dosages of dipyridamole (10, 30 and 100 mg?min21?dl21 of
forearm volume) into the brachial artery (10).
2) Subsequently, we measured the vasodilator response to 2
minutes and 5 minutes of arterial occlusion (‘post-occlusive
reactive hyperemia’ (PORH)). Forearm ischemia was induced
by inflation of an upper arm cuff to 200 mmHg, as described
previously [13]. PORH was used as a stimulus for increased
endogenous extracellular adenosine formation.
3) Finally, on day 7, we measured FBF during simultaneous
adm in i s t r a t i on o f d i p y r i d amo l e ( 1 0 , 30 and
100 mg?min21?dl21) and the adenosine receptor antagonist
caffeine (90 mg?min21?dl21) into the brachial artery.
On day 8, we recorded the forearm vasodilator response to the
administration of sodium nitroprusside (SNP) (0.6 and
0.06 mg?min21?dl21) and adenosine (1.5 and 5.0 mg?min21?dl21)
to exclude non-specific effects of eplerenone on vasomotor
function and adenosine sensitivity. Figure 1 illustrates the design
of the study.
Blood and urine sampling
Three to 5 days after the start of the study medication, the
plasma potassium concentration was measured in venous blood.
Volunteers were excluded and study medication was discontinued
if the serum potassium was $5.1 mmol/l.
At day 6, the participants collected a 24-hours urine sample.
Urinary sodium and creatinine were determined to ensure that salt
intake was approximately the same during both treatment periods.
Before the experiment on day 7, blood was drawn for the
determination of potassium, sodium, creatinine, plasma caffeine
concentration (to check compliance with caffeine abstinence),
aldosterone, renin, and plasma eplerenone concentration. On day
8 we measured the plasma caffeine concentration only. Subjects
with a circulating caffeine concentration .1.0 mg/l were exclud-
ed from analyses.
Analytic procedures
Plasma caffeine concentrations were determined using reversed-
phase HPLC with ultraviolet detection set at 273 nm, according to
Schreiber-Deturmeny and Bruguerolle [19]. After data monitoring
The Effect of Eplerenone on Adenosine Formation in Humans In Vivo
PLOS ONE | www.plosone.org 2 October 2014 | Volume 9 | Issue 10 | e111248
and data lock, eplerenone concentrations were determined by LC-
MSMS. Liquid chromatographic separation was performed at a
temperature of 30uC with a mobile phase consisting of solvent A
(0.1% (v/v) formic acid (HCOOH) in water) and solvent B (0.1%
(v/v) HCOOH in acetonitrile). For the mass spectrometric
analysis, heated electrospray ionization was operated at a spray
voltage of +4.5 kV, a capillary temperature of 225uC and a
vaporizer temperature of 382uC. Positive ion mode was used with
selected reaction monitoring for the quantitative analysis of
eplerenone, using the most abundant product ion for quantifica-
tion.
Outcomes
The primary outcome was the FBF response to the intrabrachial
administration of incremental dosages of dipyridamole, after
treatment with eplerenone, compared to placebo.
Secondary outcomes were the FBF response to the intrabrachial
administration of incremental dosages of dipyridamole with
concomitant administration of caffeine, and the FBF response to
incremental periods of arterial occlusion.
Statistical analysis
For sample size calculation, we assumed a 25% increase in the
primary endpoint, a standard deviation of the logarithm of the
FBF of 0.35, and a correlation between both experiments of 0.7.
This assumption was based on the previous findings that MR
antagonists reduced infarct size in preclinical studies with
approximately 30% [6], and that rosuvastatin, which increases
CD73 activity with approximately 50% approximately doubles
dipyridamole-induced forearm vasodilation [13,17]. The power of
the study was set at 80% with a two-sided alpha of 0.05. As results,
12 evaluable subjects were needed. In order to have 12 evaluable
subjects, we included 14 eligible participants.
FBF analyses were done offline before unblinding of the study.
We averaged all individual FBF responses during the last 4
minutes of the baseline FBF (normal saline), the last 2 minutes of
the FBF response to dipyridamole, sodium nitroprusside, and
adenosine. For the PORH, we selected the highest FBF after
reperfusion and also averaged FBF values for each consecutive
minute. Results are expressed as the median absolute FBF
(interquartile range) in ml?dl21?min21. In an additional analysis,
to correct for any possible systemic effects on FBF during the
experiments, we divided the FBF in the experimental arm by the
FBF in the non-experimental arm. This analysis was performed
with untransformed data.
A linear mixed model was used to compare differences between
the treatments, with the log FBF during placebo and eplerenone
treatment as the dependent variable with the following fixed
factors: treatment (eplerenone versus placebo), dose, period, and
the interaction between treatment and dose. To correct for
repeated measurements, we used a heterogeneous compound
symmetry structure for the residuals.
For the comparison of the plasma potassium values, blood
pressure, and heart rate on a single moment as well as the
measurements in the 24 hours urine samples and plasma sodium,
serum aldosterone, and plasma renin values, we used a paired
sample t-test, after testing for normality.
Results
Subjects
Screening was performed in the period 18-04-2013 until 22-10-
2013 and the experiments were performed in the period from 08-
05-2013 until 23-12-2013. We screened 20 subjects for eligibility.
Two participants withdrew from participation and 4 participants
were excluded, because of a DBP ,60 mmHg (n = 3), and a SBP
.140 Hg (n = 1). The baseline characteristics are depicted in
Table 1.
FBF responses to the different stimuli were obtained in all 14
subjects, with the exception of the FBF response to SNP and
adenosine in 1 subject, because insertion of the arterial needle
failed. All baseline plasma caffeine concentrations were below
0.6 mg/l, and therefore none of the subjects had to be excluded
from analysis. Please see Figure 2 for the flow diagram of the
various different phases of this cross-over trial.
Eplerenone treatment did not significantly affect blood pressure
and serum potassium, but there was a significant decrease in the
plasma sodium concentration (Table 2). Urinary sodium concen-
tration did not significantly differ between placebo and eplerenone
treatment. Furthermore, eplerenone treatment almost doubled the
serum aldosterone and plasma renin concentrations (p,0.05), with
an unchanged aldosterone-to-renin-ratio (Table 2; p=0.30).
Outcomes
Baseline FBF before intra-arterial infusion of dipyridamole was
1.34 (0.82) ml?dl21?min21 during placebo and 1.47 (1.05)
ml?dl21?min21 during eplerenone treatment. The incremental
dosages of dipyridamole increased FBF in the experimental arm to
1.63 (0.60), 2.13 (1.51) and 2.71 (1.32) ml?dl21?min21, and 2.00
(1.45), 2.68 (1.87) and 3.22 (1.94) ml?dl21?min21 during placebo
and eplerenone treatment, respectively. There was no significant
Figure 1. Schematic overview of the experimental protocol.
doi:10.1371/journal.pone.0111248.g001
The Effect of Eplerenone on Adenosine Formation in Humans In Vivo
PLOS ONE | www.plosone.org 3 October 2014 | Volume 9 | Issue 10 | e111248
Table 1. Baseline characteristics of the male participants.
Characteristic Value
Age - years 21.963.0
BMI - kg/m2 23.661.9
Blood pressure - mmHg
SBP 12768
DBP 7068
Heart rate – beats/min 5969
Blood plasma
Potassium - mmol/L 3.960.3
Creatinine - mmol/L 82.269.7
Non-fasting glucose - mmol/L 5.360.6
ALAT - U/L 30.065.3
Non-fasting cholesterol - mmol/L 3.860.6
doi:10.1371/journal.pone.0111248.t001
Figure 2. Consort 2010 flow diagram.
doi:10.1371/journal.pone.0111248.g002
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increase in FBF response to dipyridamole during eplerenone
treatment compared to the placebo experiment (Figure 3A;
p=0.51). Similarly, the FBF ratio did not differ between placebo
and eplerenone treatment (p=0.79). In none of the experiments
changes in FBF in the non-experimental arm were observed.
Caffeine significantly blunted the dipyridamole-induced vaso-
dilator response during placebo and eplerenone treatment (p,
0.001), but there was no difference between both treatment
periods (Figure 3B; p=0.98).
The peak (absolute) FBF’s after 2 and 5 minutes of arterial
occlusion were 20.00 (9.73) and 27.6 (7.45) ml?dl21?min21
respectively during placebo, and 23.05 (12.35) and 27.75 (16.05)
ml?dl21?min21 respectively during eplerenone use (p=0.91).
Figure 4 shows that the PORH after 2 minutes of arterial
occlusion was not potentiated by eplerenone (p=0.73). The
averaged FBF after 5 minutes of arterial occlusion was 11.24 (4.94)
in the 1st minute, 3.18 (1.52) in the 2nd minute, and 2.42 (0.99)
ml?dl21?min21 in the 3rd minute after arterial occlusion during
placebo use. During eplerenone treatment, FBF was 11.97 (6.60),
2.65 (2.14), and 2.72 (1.78) ml?dl21?min21 in the first 3 minutes
after 5 minutes of arterial occlusion. Eplerenone did not potentiate
the PORH after 5 minutes of arterial occlusion (p=0.58).
Table 2. Hemodynamic and laboratory values during the study.
Placebo Eplerenone p-value
Blood plasma
Potassium day 3–5 - mmol/L 3.960.26 3.960.28 0.78
Potassium day 7 - mmol/L 3.660.23 3.760.27 0.12
Sodium day 7 - mmol/L 140.061.4 139.161.4 ,0.05
Creatinine day 7 -mmol/L 82.166.8 84.666.4 ,0.05
Aldosterone day 7 - nmol/L 0.6560.41 1.2060.50 ,0.05
Renin day 7- mE/L 27.7618.1 44.8626.7 ,0.05
ARR 34.2621.0 38.0616.9 0.30
24 hr urine (day 6)
Total amount - mL 1475.66520.0 1635.46677.4 0.34
Sodium - mmol/L 85.7650.3 104.7644.4 0.15
Creatinin - mmol/L 13.366.2 12.065.2 0.52
Blood pressure - mmHg
SBP day 3–5 12669 12967 0.57
DBP day 3–5 6567 67611 0.54
SBP day 7 123610 12068 0.19
DBP day 7 62610 62.668 0.58
SBP day 8 124611 126610 0.52
DBP day 8 6568 6366 0.34
Heart rate - beats per minute
HR day 3–5 63610 6269 0.42
HR day 7 59611 58610 0.51
HR day 8 61611 6067 0.74
doi:10.1371/journal.pone.0111248.t002
Figure 3. FBF response to dipyridamole, without and with caffeine. FBF response to A dipyridamole and B dipyridamole (D) in incremental
dosages during concomitant administration of caffeine (C) in a constant dosage of 90 mg?dL21?min21, during placebo (grey) and eplerenone (black)
treatment in the experimental (filled squares) and non-experimental (open squares) arm.
doi:10.1371/journal.pone.0111248.g003
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The vasodilator response to SNP and adenosine did not differ
between placebo and eplerenone treatment (Figure 5).
The plasma eplerenone concentration on t = 0 was
0.1760.13 mg/ml (mean 6 SD). During placebo, the eplerenone
concentration was 0.0 mg/ml in all cases.
Safety
There were no serious adverse events. In none of the subjects,
serum potassium exceeded 4.6 mmol/l. Thirteen adverse events
occurred in 9 different participants. During eplerenone treatment
1 subject experienced a short period of abdominal pain on day 4 of
the treatment and another subject had a mild headache on day 7.
During placebo use 2 subjects had a short period of headache, 1
subject experienced light headedness during sports activities, 1
subject had symptoms of hay fever and another subject developed
a skin rash. Due to dislocation of the arterial needle, a very small
amount of the infused volume was administered extra-arterially in
3 subjects. Another subject developed 3 small, pulsating, yellowish
hives just medial from the arterial needle during dipyridamole
infusion, which resolved spontaneously. One subject experienced
pain in his left shoulder during the experiment, which resolved
after we repositioned the participant. Finally, 1 subject developed
a forearm hematoma after several unsuccessful attempts to
cannulate the brachial artery on day 8.
Discussion
This study indicates that the selective MR antagonist epler-
enone does not have an effect on the extracellular adenosine
formation in humans in vivo, excluding this mechanism as an
explanation for the beneficial cardiovascular effects of MR
antagonism observed in patients with heart failure.
The Randomized Aldactone Evaluation Study (RALES),
Eplerenone Post–acute myocardial infarction Heart failure Effi-
cacy and Survival Study (EPHESUS), and Eplerenone in Mild
Patients Hospitalization And Survival Study in Heart Failure
(EMPHASIS-HF) showed that treatment with MR antagonists
reduces the mortality and the number of hospitalizations in
patients with mild to severe systolic heart failure [2–4]. In animal
models of myocardial infarction, MR antagonists limit infarct size
when administered either prior to ischemia or just before the onset
of reperfusion, and protect against cardiac remodeling, as
reviewed by van den Berg et al. [20].
The underlying mechanism of the beneficial effects of MR
antagonists in patients is not yet understood. However, results
from animal studies suggest that extracellular adenosine formation
is crucial for the protective effect of MR antagonists against
myocardial IR injury. In an elegant series of experiments in mice
and rabbits, Schmidt et al. showed that the MR antagonists
canrenoate and eplerenone reduce infarct size in a dose-dependent
manner. Moreover, by using pharmacological approaches and
models of targeted gene deletion, the investigators convincingly
demonstrated an important role for endogenous adenosine in the
cardioprotective effect. The infarct size-limiting effect of canreno-
ate was completely abolished in CD73 knock-out mice and in
adenosine A2b receptor knock-out mice. Similar results were
obtained in isolated rat hearts. In rats, administration of
eplerenone at 10 mM at the moment of reperfusion resulted in a
reduction of the infarct size from 40 to 10%, which was completely
blocked by co-administration of the adenosine receptor blocker
8p-sulfophenyladenosine [6].
Based on this series of experiments, we hypothesized that the
selective MR antagonist eplerenone increases extracellular forma-
tion of adenosine, by activation of the enzyme CD73. Interest-
ingly, increased endogenous adenosine receptor stimulation has
also been implicated in the cardioprotective effect of other drugs,
including statins, methotrexate and metformin [12,21,22].
It is difficult to investigate the potential effects of drugs on
endogenous adenosine because the half life of adenosine in blood is
extremely short due to rapid uptake and degradation of adenosine
by erythrocytes and endothelial cells [16]. In a normal physiolog-
ical situation, the transmembranous adenosine concentration
gradient drives extracellular adenosine into the cytosol [23]. The
Figure 4. PORH after 2 minutes of arterial occlusion. PORH in the
first 3 minutes after 2 minutes of arterial occlusion during placebo
(grey) and eplerenone (black) treatment in the experimental (filled
squares) and non-experimental (open squares) arm.
doi:10.1371/journal.pone.0111248.g004
Figure 5. FBF response to sodium nitroprusside (SNP) and adenosine. The FBF response to A sodium nitroprusside (SNP) and B adenosine,
during placebo (grey) and eplerenone (black) treatment in the experimental arm (filled squares) and non-experimental arm (open squares).
doi:10.1371/journal.pone.0111248.g005
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ENT-inhibitor dipyridamole inhibits this facilitated diffusion and
thereby increases the extracellular adenosine concentration, which
can subsequently activate membrane-bound adenosine receptors
at the site of adenosine formation [16,24]. These observations
justify the use of dipyridamole-induced vasodilation as a read-out
of extracellular adenosine formation. We have previously shown,
using a similar experimental design as the present study, that
rosuvastatin augments dipyridamole-induced forearm vasodilation
and post-occlusive reactive hyperemia and limits forearm ische-
mia-reperfusion injury via adenosine receptor stimulation [13,17].
Moreover, rosuvastatin increased the activity of CD73 on
circulating human mononuclear cells [13].
In the present study, we could not confirm a relation between
treatment with eplerenone and the extracellular adenosine system
in healthy humans in vivo. We showed that a one-week treatment
with eplerenone 50 mg bid does not potentiate dipyridamole-
induced vasodilation and does not affect PORH after 2 and 5
minutes of arterial occlusion. These findings are in sharp contrast
to the previous observations in animal models of myocardial
infarction [6].
How can this discrepancy be explained? First, it has been
recognized that many promising findings in animal study cannot
be confirmed in human studies [25]. In general, this translational
failure can be explained by methodological shortcomings in
animal studies, e.g. the lack of a formal sample size calculation,
selection bias due to the lack of randomization, unblinded
researchers, and inadequate statistical analyses [25]. The scientific
basis for our hypothesis is based on only one preclinical study by
Schmidt et al [6]. This study, however, described a series of
experiments in which a pivotal role for endogenous adenosine in
the infarct size-limiting effect of the MR antagonists canrenoate
and eplerenone was consistently observed in different animal
species and by using various methodological approaches, including
pharmacological inhibitor studies and gene deletion models.
Translational failure could also result from fundamental differ-
ences between the animal models and the human situation. With
regard to adenosine metabolism, it is known for fundamental
differences exists between rats and humans (e.g. the rat ENT1
transporter is less sensitive to inhibition with dipyridamole than
the human ENT1) [26]. However, other drugs that modulate
adenosine levels seem equally effective in humans and in animal
models [17,21,22,27]. Thirdly, a major difference in drug
concentration between the animal studies and the human situation
is often present. In our study, the circulating eplerenone
concentration immediately before the intake of the last medication
dose (trough concentration) averaged 0.17 mg/ml (0.41 mM).
Given a bioavailability of 70%, and an apparent volume of
distribution of 43–90 liters, the eplerenone concentration at the
moment of the experiment is approximately 1.7 mM. In a rat
Langendorff model, in which the heart is perfused with a buffer
solution [6], a cardioprotective effect of eplerenone was observed
with 10 mM, but not with 1 mM. Given a plasma protein binding
of 50%, the effective concentration in the rat study is approx-
imately 10-times higher than the concentration in our study. We
used 50 mg of eplerenone bid, which is higher than the dosages
administered in the clinical trials in patients with heart failure in
which eplerenone showed beneficial effects [3,4]. Therefore, we
cannot exclude that eplerenone does affect adenosine formation at
higher concentrations, which are not relevant however for the
clinical situation. In addition, in our study, eplerenone was
administered during one week, in contrast to the single dose
administration in the animal studies. As expected, the serum
aldosterone and plasma renine levels had almost doubled after 6
days of treatment with eplerenone. Although this increase in
aldosterone does probably not affect our results, because
eplerenone blocks the MR, MR-independent effects of aldosterone
have been described previously (20). In theory, any non-MR-
mediated effects of aldosterone on adenosine metabolism might
have influenced our result. Finally, it is important to realize that
our experiments were performed in healthy subjects, and not in
patients with cardiovascular disease or heart failure. This was done
because we aimed to demonstrate a general pharmacological
mechanism of eplerenone and also because the preclinical studies
that were fundamental to our hypothesis were performed in
healthy animals. We cannot exclude, however, that the effects of
MR antagonists are different in patients with cardiovascular
disease, such as heart failure.
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